XORTX Therapeutics Inc.
$2.25
▲
1.3%
2026-04-21 10:22:01
www.xortx.com
NCM: XRTX
Explore XORTX Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.16 M
Current Price
$2.25
52W High / Low
$9.85 / $2.42
Stock P/E
—
Book Value
$0.3
Dividend Yield
—
ROCE
-156.2%
ROE
-98%
Face Value
—
EPS
$-2.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.09
Debt / Equity
1.79
Current Ratio
2.1
Quick Ratio
2.11
Forward P/E
3.11
Price / Sales
—
Enterprise Value
$2.64 M
EV / EBITDA
-1.05
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 2. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 3. | Caribou Biosciences, Inc. | $2.29 | — | $212.6 M | — | -90.82% | -78.97% | $3.54 / $0.71 | $1.28 |
| 4. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 5. | Korro Bio, Inc. | $14.28 | — | $207.54 M | — | -85.99% | -1.11% | $55.89 / $5.2 | $5.46 |
| 6. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 7. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.69 M | -0.72 M | -0.89 M | -0.96 M | -0.66 M | — |
| Net Profit | -0.59 M | -0.65 M | -0.72 M | -0.7 M | 0.12 M | — |
| EPS in Rs | -0.42 | -0.47 | -0.52 | -0.5 | 0.09 | -0.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -3.26 M | -4.12 M | -6.05 M | -10.29 M |
| Net Profit | -2.66 M | -3.31 M | -2.16 M | -7.72 M |
| EPS in Rs | -1.91 | -2.38 | -1.55 | -5.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.68 M | 4.09 M | 5.47 M | 12.37 M |
| Total Liabilities | 0.6 M | 0.76 M | 0.83 M | 5.38 M |
| Equity | 2.08 M | 3.34 M | 4.64 M | 7 M |
| Current Assets | 1.26 M | 2.68 M | 4.07 M | 10.9 M |
| Current Liabilities | 0.6 M | 0.76 M | 0.83 M | 1.51 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.77 M | -3.68 M | -6.58 M | -8.17 M |
| Investing CF | -0.29 M | -0.04 M | -0.05 M | -0.05 M |
| Financing CF | 1.43 M | 2.78 M | -0.36 M | 3.91 M |
| Free CF | -2.82 M | -3.72 M | -6.63 M | -8.21 M |
| Capex | -0.06 M | -0.04 M | -0.05 M | -0.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -53.53% | 72.04% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-04-06 | 1:0.2 |
| 2023-11-14 | 1:0.111111 |
| 2023-11-10 | 1:0.111111 |